Tatiana Fedorova

Tatiana Fedorova


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
OKOlga Kulikova
Olga Kulikova
DBDaniil Berezhnoy
Daniil Berezhnoy
SSSergey L. Stvolinsky
Sergey L. Stvolinsky
ALAlexander V Lopachev
Alexander V Lopachev
VOValentina S. Orlova
Valentina S. Orlova
TFTatiana Fedorova
Tatiana Fedorova

29 May 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
NANadezda Azbukina
Nadezda Azbukina
ALAlexander V Lopachev
Alexander V Lopachev
DCDmitry Chistyakov
Dmitry Chistyakov
SGSergey Goriainov
Sergey Goriainov
AAAlina A. Astakhova
Alina A. Astakhova
MSMarina Sergeeva
Marina Sergeeva
Wilson’s disease (WD) is a rare autosomal recessive metabolic disorder resulting from mutations in the copper-transporting, P-type ATPase gene ATP7B gene, but influences of epigenetics, environment, age, and sex-related factors on the WD phenotype complicate diagnosis and clinical manifestations. Oxylipins, derivatives of omega-3, and omega-6 polyunsaturated fatty acids (PUFAs) are signaling mediators that are deeply involved in innate immunity responses; the regulation of inflammatory responses, including acute and chronic inflammation; and other disturbances related to any system diseases. Therefore, oxylipin profile tests are attractive for the diagnosis of WD. With UPLC-MS/MS lipidomics analysis, we detected 43 oxylipins in the plasma profiles of 39 patients with various clinical manifestations of WD compared with 16 healthy controls (HCs). Analyzing the similarity matrix of oxylipin profiles allowed us to cluster patients into three groups. Analysis of the data by VolcanoPlot and partial least square discriminant analysis (PLS-DA) showed that eight oxylipins and lipids stand for the variance between WD and HCs: eicosapentaenoic acid EPA, oleoylethanolamide OEA, octadecadienoic acids 9-HODE, 9-KODE, 12-hydroxyheptadecatrenoic acid 12-HHT, prostaglandins PGD2, PGE2, and 14,15-dihydroxyeicosatrienoic acids 14,15-DHET. The compounds indicate the involvement of oxidative stress damage, inflammatory processes, and peroxisome proliferator-activated receptor (PPAR) signaling pathways in this disease. The data reveal novel possible therapeutic targets and intervention strategies for treating WD.

1 October 2019 in Neurochemical Journal
Verified
Journal Article
Closed access
PDF file
TFTatiana Fedorova
Tatiana Fedorova
ALA. A. Logvinenko
A. A. Logvinenko
VPV. V. Poleshchuk
V. V. Poleshchuk
OMO. A. Muzychuk
O. A. Muzychuk
ASA. A. Shabalina
A. A. Shabalina
SIS. N. Illarioshkin
S. N. Illarioshkin
—Oxidative stress (OS) plays a significant role in the pathogenesis of Parkinson’s disease (PD) and is accompanied by the development of free radical reactions of lipid peroxidation. The...

1 March 2009 in Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology
Verified
Journal Article
Closed access
PDF file
TFTatiana Fedorova
Tatiana Fedorova
MBM. S. Belyaev
M. S. Belyaev
OTO. A. Trunova
O. A. Trunova
VGV. V. Gnezditsky
V. V. Gnezditsky
MMM. Yu. Maximova
M. Yu. Maximova
ABA. A. Boldyrev
A. A. Boldyrev
Carnosine administration (in a daily dose of 2 g) as an additional therapy for patients with chronic discirculatory encephalopathy (DE) results in an increase in stability of blood plasma lipoproteins toward Fe2+-induced oxidation and stabilization of red blood cells against acidic hemolysis as well as intensification of respiratory burst of periphery blood leucocytes. At the same time, latent period of brain induced potentials, P300, decreases and the proportion of the high-amplitude induced potentials increases. The data presented demonstrate that carnosine enhances the efficiency of basal therapy of DE patients.

9 November 2012 in Interdisciplinary Toxicology
Verified
Journal Article
Open access
PDF file
FDFrantisek Drafi
Frantisek Drafi
Katarina BauerovaKatarina Bauerova
Katarina Bauerova
VKViera Kuncirova
Viera Kuncirova
CSCentre of Experimental Medicine Slovak Academy Sciences
Centre of Experimental Medicine Slovak Academy Sciences
DMDanica Mihalova
Danica Mihalova
RNRadomir Nosal
Radomir Nosal
Oxygen metabolism has an important role in the pathogenesis of rheumatoid arthritis. A certain correlation was observed between oxidative stress, arthritis and the immune system. Reactive oxygen species produced in the course of cellular oxidative phosphorylation and by activated phagocytic cells during oxidative burst, exceed the physiological buffering capacity and result in oxidative stress. The excessive production of ROS can damage protein, lipids, nucleic acids, and matrix components. Patients with rheumatoid arthritis have an altered antioxidant defense capacity barrier. In the present study the effect of substances with antioxidative properties, i.e. pinosylvin and carnosine, was determined in monotherapy for the treatment of adjuvant arthritis (AA). Moreover carnosine was evaluated in combination therapy with methotrexate. Rats with AA were administered first pinosylvin (30 mg/kg body mass daily per os), second carnosine (150 mg/kg body mass daily per os) in monotherapy for a period of 28 days. Further, rats with AA were administered methotrexate (0.3 mg/kg body mass 2-times weekly per os), and a combination of methotrexate+carnosine, with the carnosine dose being the same as in the previous experiment. Parameters, i.e. changes in hind paw volume and arthritic score were determined in rats as indicators of destructive arthritis-associated clinical changes. Plasmatic levels of TBARS and lag time of Fe2+- induced lipid peroxidation (tau-FeLP) in plasma and brain were specified as markers of oxidation. Plasmatic level of CRP and activity of γ-glutamyltransferase (GGT) in spleen and joint were used as inflammation markers. In comparison to pinosylvin, administration of carnosine monotherapy led to a significant decrease in the majority of the parameters studied. In the combination treatment with methotrexate+carnosine most parameters monitored were improved more remarkably than by methotrexate alone. Carnosine can increase the disease-modifying effect of methotrexate treatment in rat AA.

16 February 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DTDmitry Troshev
Dmitry Troshev
DVDmitry N Voronkov
Dmitry N Voronkov
APAnastasia Pavlova
Anastasia Pavlova
DADenis Abaimov
Denis Abaimov
ALAlexander Latanov
Alexander Latanov
DBDaniil Berezhnoy
Daniil Berezhnoy
Parkinson’s disease (PD) is characterized by slow progression with a long prodromal stage and the gradual evolution of both neuropsychological symptoms and subtle motor changes, preceding motor dysfunction. Thus, in order for animal models of PD to be valid, they should reproduce these characteristics of the disease. One of such models, in which neuropathology is induced by chronic injections of low doses of mitochondrial toxin rotenone, is well established in rats. However, data on this model adapted to mice remain controversial. We have designed the study to describe the timecourse of motor and non-motor symptoms during chronic subcutaneous administration of rotenone (4 mg/kg daily for 35 days) in C57BL/6 mice. We characterize the underlying neuropathological processes (dopaminergic neuron degeneration, regional brain metabolism, monoamine neurotransmitter and lipid peroxidation changes) at different timepoints: 1 day, 2 weeks and 5 weeks of daily rotenone exposure. Based on the behavioral data, we can describe three stages of pathology: cognitive changes from week 2 of rotenone exposure, subtle motor changes in week 3–4 and motor dysfunction starting roughly from week 4. Neuropathological changes in this model include a general decrease in COX activity in different areas of the brain (acute effect of rotenone) and a more specific decrease in midbrain (chronic effect), followed by significant neurodegeneration in SNpc but not VTA by the 5th week of rotenone exposure. However, we were unable to find changes in the level of monoamine neurotransmitters neither in the striatum nor in the cortex, nor in the level of lipid peroxidation in the brainstem. Thus, the gradual progression of pathology in this model is linked with metabolic changes, rather than with oxidative stress or tonic neurotransmitter release levels. Overall, this study supports the idea that a low-dose rotenone mouse model can also reproduce different stages of PD as well as rats.